A citation-based method for searching scientific literature

Vincenza Conteduca, Alessandra Mosca, Nicole Brighi, Ugo de Giorgi, Pasquale Rescigno. Cells 2021
Times Cited: 9







List of co-cited articles
37 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
V Conteduca, D Wetterskog, M T A Sharabiani, E Grande, M P Fernandez-Perez, A Jayaram, S Salvi, D Castellano, A Romanel, C Lolli,[...]. Ann Oncol 2017
174
55

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
44

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Howard I Scher, Michael J Morris, Walter M Stadler, Celestia Higano, Ethan Basch, Karim Fizazi, Emmanuel S Antonarakis, Tomasz M Beer, Michael A Carducci, Kim N Chi,[...]. J Clin Oncol 2016
694
44

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, Daniel Wetterskog, Samanta Salvi, Giorgia Gurioli, Emanuela Scarpi, Elena Castro, Mercedes Marin-Aguilera, Cristian Lolli,[...]. Eur Urol 2019
47
33

Plasma AR and abiraterone-resistant prostate cancer.
Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca, Anuradha Jayaram, Nicola Casiraghi, Daniel Wetterskog, Samanta Salvi, Dino Amadori, Zafeiris Zafeiriou, Pasquale Rescigno,[...]. Sci Transl Med 2015
307
33

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Alexander W Wyatt, Arun A Azad, Stanislav V Volik, Matti Annala, Kevin Beja, Brian McConeghy, Anne Haegert, Evan W Warner, Fan Mo, Sonal Brahmbhatt,[...]. JAMA Oncol 2016
227
33

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Alexander W Wyatt, Matti Annala, Rahul Aggarwal, Kevin Beja, Felix Feng, Jack Youngren, Adam Foye, Paul Lloyd, Matti Nykter, Tomasz M Beer,[...]. J Natl Cancer Inst 2017
190
33

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Takayuki Sumiyoshi, Kei Mizuno, Toshinari Yamasaki, Yu Miyazaki, Yuki Makino, Kosuke Okasho, Xin Li, Noriaki Utsunomiya, Takayuki Goto, Takashi Kobayashi,[...]. Sci Rep 2019
39
22

Chemistry and structural biology of androgen receptor.
Wenqing Gao, Casey E Bohl, James T Dalton. Chem Rev 2005
334
22

Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Axel S Merseburger, Nick Waldron, Maria J Ribal, Axel Heidenreich, Sven Perner, Karim Fizazi, Cora N Sternberg, Joaquin Mateo, Manfred P Wirth, Elena Castro,[...]. Eur Urol 2021
9
22

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Adam Sharp, Ilsa Coleman, Wei Yuan, Cynthia Sprenger, David Dolling, Daniel Nava Rodrigues, Joshua W Russo, Ines Figueiredo, Claudia Bertan, George Seed,[...]. J Clin Invest 2019
165
22

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
Samanta Salvi, Valentina Casadio, Vincenza Conteduca, Cristian Lolli, Giorgia Gurioli, Filippo Martignano, Giuseppe Schepisi, Sara Testoni, Emanuela Scarpi, Dino Amadori,[...]. Oncotarget 2016
55
22

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Emmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J Hoimes, Ulka Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko,[...]. J Clin Oncol 2020
244
22

Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Himisha Beltran, Alessandro Romanel, Vincenza Conteduca, Nicola Casiraghi, Michael Sigouros, Gian Marco Franceschini, Francesco Orlando, Tarcisio Fedrizzi, Sheng-Yu Ku, Emma Dann,[...]. J Clin Invest 2020
59
22

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Stéphane Oudard, Karim Fizazi, Lisa Sengeløv, Gedske Daugaard, Fred Saad, Steinbjørn Hansen, Marie Hjälm-Eriksson, Jacek Jassem, Antoine Thiery-Vuillemin, Orazio Caffo,[...]. J Clin Oncol 2017
164
22

When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients.
Chiara Foroni, Natasa Zarovni, Laura Bianciardi, Simona Bernardi, Luca Triggiani, Davide Zocco, Marta Venturella, Antonio Chiesi, Francesca Valcamonico, Alfredo Berruti. Biomedicines 2020
23
22

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Nicholas D James, Matthew R Sydes, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Christopher C Parker, J Martin Russell, Gerhardt Attard,[...]. Lancet 2016
22


Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
22

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, Mary Nakazawa, Jeffrey C Roeser, Yan Chen, Tabrez A Mohammad, Yidong Chen, Helen L Fedor,[...]. N Engl J Med 2014
22

Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy.
Mara P Steinkamp, Orla A O'Mahony, Michele Brogley, Haniya Rehman, Elizabeth W Lapensee, Saravana Dhanasekaran, Matthias D Hofer, Rainer Kuefer, Arul Chinnaiyan, Mark A Rubin,[...]. Cancer Res 2009
149
22

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Shihua Sun, Cynthia C T Sprenger, Robert L Vessella, Kathleen Haugk, Kathryn Soriano, Elahe A Mostaghel, Stephanie T Page, Ilsa M Coleman, Holly M Nguyen, Huiying Sun,[...]. J Clin Invest 2010
527
22

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Arun A Azad, Stanislav V Volik, Alexander W Wyatt, Anne Haegert, Stephane Le Bihan, Robert H Bell, Shawn A Anderson, Brian McConeghy, Robert Shukin, Jenny Bazov,[...]. Clin Cancer Res 2015
327
22

Integrative genomic profiling of human prostate cancer.
Barry S Taylor, Nikolaus Schultz, Haley Hieronymus, Anuradha Gopalan, Yonghong Xiao, Brett S Carver, Vivek K Arora, Poorvi Kaushik, Ethan Cerami, Boris Reva,[...]. Cancer Cell 2010
22

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.
Pernelle Lavaud, Clément Dumont, Constance Thibault, Laurence Albiges, Giulia Baciarello, Emeline Colomba, Ronan Flippot, Alina Fuerea, Yohann Loriot, Karim Fizazi. Ther Adv Med Oncol 2020
4
50

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Heini M L Kallio, Reija Hieta, Leena Latonen, Anniina Brofeldt, Matti Annala, Kati Kivinummi, Teuvo L Tammela, Matti Nykter, William B Isaacs, Hans G Lilja,[...]. Br J Cancer 2018
40
22

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer.
Vincenza Conteduca, Elena Castro, Daniel Wetterskog, Emanuela Scarpi, Anuradha Jayaram, Nuria Romero-Laorden, David Olmos, Giorgia Gurioli, Cristian Lolli, Maria Isabel Sáez,[...]. Eur J Cancer 2019
24
22

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Daniel P Petrylak, Catherine M Tangen, Maha H A Hussain, Primo N Lara, Jeffrey A Jones, Mary Ellen Taplin, Patrick A Burch, Donna Berry, Carol Moinpour, Manish Kohli,[...]. N Engl J Med 2004
22

Biological Evolution of Castration-resistant Prostate Cancer.
Alastair Davies, Vincenza Conteduca, Amina Zoubeidi, Himisha Beltran. Eur Urol Focus 2019
38
22


TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost, Wim Demey,[...]. Clin Cancer Res 2019
83
22

Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
Isabel Coutinho, Tanya K Day, Wayne D Tilley, Luke A Selth. Endocr Relat Cancer 2016
99
22

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Roberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, Susana Miranda, Ines Figueiredo, Pasquale Rescigno, Praful Ravi, Carmel Pezaro, Aurelius Omlin, David Lorente,[...]. Eur Urol 2015
147
22

Clinical relevance of androgen receptor alterations in prostate cancer.
Emma Jernberg, Anders Bergh, Pernilla Wikström. Endocr Connect 2017
47
22

Genomic correlates of clinical outcome in advanced prostate cancer.
Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia, Ilsa Coleman, Marcin Cieslik, Matteo Benelli, Dan Robinson, Eliezer M Van Allen,[...]. Proc Natl Acad Sci U S A 2019
418
22

Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.
Paymaneh D Malihi, Ryon P Graf, Angel Rodriguez, Naveen Ramesh, Jerry Lee, Ramsay Sutton, Rhett Jiles, Carmen Ruiz Velasco, Emi Sei, Anand Kolatkar,[...]. Clin Cancer Res 2020
35
22

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Jane Goodall, Joaquin Mateo, Wei Yuan, Helen Mossop, Nuria Porta, Susana Miranda, Raquel Perez-Lopez, David Dolling, Dan R Robinson, Shahneen Sandhu,[...]. Cancer Discov 2017
243
22


Expression of luteinizing hormone releasing hormone and its mRNA in human endometrial cancer cell lines.
G Irmer, C Bürger, O Ortmann, K D Schulz, G Emons. J Clin Endocrinol Metab 1994
56
11



Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.
Kathryn E Ware, Mariano A Garcia-Blanco, Andrew J Armstrong, Scott M Dehm. Endocr Relat Cancer 2014
99
11

Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Mohammad Abufaraj, Takehiro Iwata, Shoji Kimura, Anoud Haddad, Hashim Al-Ani, Lana Abusubaih, Marco Moschini, Alberto Briganti, Pierre I Karakiewicz, Shahrokh F Shariat. Eur Urol 2021
34
11

Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Zhonglin Cai, Weijie Chen, Jianzhong Zhang, Hongjun Li. Int Urol Nephrol 2018
11
11


Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Yingming Li, Siu Chiu Chan, Lucas J Brand, Tae Hyun Hwang, Kevin A T Silverstein, Scott M Dehm. Cancer Res 2013
464
11

Prostate cancer.
Richard J Rebello, Christoph Oing, Karen E Knudsen, Stacy Loeb, David C Johnson, Robert E Reiter, Silke Gillessen, Theodorus Van der Kwast, Robert G Bristow. Nat Rev Dis Primers 2021
65
11

Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
Jinpei Kumagai, Johannes Hofland, Sigrun Erkens-Schulze, Natasja F J Dits, Jacobie Steenbergen, Guido Jenster, Yukio Homma, Frank H de Jong, Wytske M van Weerden. Prostate 2013
30
11


Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors.
Craig A McArdle, J Franklin, L Green, J N Hislop. J Endocrinol 2002
130
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.